PUBLICATIONS

RECENT PRESENTATIONS

W Ma, et al. A First-In-Human Phase I open-label study of a novel cancer vaccine LabVax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas. American Society for Clinical Oncology (ASCO) 2022.

M Babich, T Li, JA Radosevich. Generation of peptide vaccines targeting labyrinthin, a pan-adenocarcinoma biomarker.  American Association for Cancer Research (AACR), 2020.

Saleeve, et al. Anti-labyrinthin monoclonal antibody reduces human adenocarcinoma circulating tumor cells in the blood of patient-derived xenograft models and inhibits the growth of adenocarcinoma cell cultures. AACR, 2019.

ANNOUNCEMENTS

Clinical Trial: A Cancer Vaccine (LabVax 3(22)-23) and GM-CSF for the Treatment of Advanced Stage Adenocarcinoma, ClinicalTrials.Gov 2021.

PAPERS

Labyrinthin: A Distinct Pan-Adenocarcinoma Diagnostic and Immunotherapeutic Tumor Specific Antigen, HELIYON, 2022.

Topology and Adenocarcinoma Cell Localization Dataset on the Labyrinthin Biomarker, bioRxiv, 2022.

Labyrinthin, the Tumor Marker Recognized by MCA 44-3A6: A Case for Pan-Tumor Markers as Targets to Treat Cancer" ONCOTARGETS AND THERAPY, 2019.

Expression of the Adenocarcinoma-Related Antigen Recognized by Monoclonal Antibody 44-3A6 in Salivary Gland Neoplasias, OTOLARYNGOLOGY HEAD & NECK SURGERY, 1998.

Monoclonal Antibody 44-3A6 as an Adjunct in Cytodiagnosis of Adenocarcinomas in Body Fluids, DIAGNOSTIC CYTOPATHOLOGY, 1992.

Changes in the Expression of the Tumor-Associated Antigen Recognized by the Monoclonal Antibody 44-3A6 in A549 Cells due to Calcium, TUMOR BIOLOGY,1991.

Expression of the Epitope Recognized by the Monoclonal Antibody 44-3A6 during Human Fetal Development, TUMOR BIOLOGY, 1991.

Application of Monoclonal Antibody 44-3A6 in the Cytological Diagnosis of Pleural Effusion and Histological Correlation in Lung Carcinoma, LUNG CANCER, 1991.

The Use of Monoclonal Antibody 44-3A6 in Cell Blocks in the Diagnosis of Lung Carcinoma, Carcinomas Metastatic to Lung and Pleura, and Pleural Malignant Mesothelioma, AMERICAN JOURNAL OF PATHOLOGY, 1991.

Cell Cycle and Electron Microscopic Evaluation of the Adenocarcinoma Antigen Recognised by the Monoclonal Antibody 44-3A6, BRITISH J. CANCER, 1991.

Monoclonal Antibody 44-3A6 as a Marker for Breast Carcinoma, TUMOR BIOLOGY, 1991.

Monoclonal Antibody 44-3A6 Doxorubicin Immunoconjugates: Comparative in vitro Anti-Tumor Efficacy of Different Conjugation, Methods" TUMOR BIOLOGY, 1991.

Immunohistochemical Analysis of Human Adenocarcinomas of the Lung Using the Monoclonal Antibody 44-3A6, TUMOR BIOLOGY, 1989.

Expression of the Antigenic Determinant Recognized by the Monoclonal Antibody 44-3A6 on Select Human Adenocarcinomas and Normal Human Tissues, TUMOR BIOLOGY, 1988.

Malignant Mesotheliomas: Improved Differential Diagnosis From Lung Adenocarcinomas Using Monoclonal Antibodies 44-3A6 and 624A12, AMERICAN JOURNAL OF PATHOLOGY, 1986.

Application of Monoclonal Antibody 44-3A6 in the Cytodiagnosis and Classification of Pulmonary Carcinomas, DIAGNOSTIC CYTOPATHOLOGY, 1985.

Monoclonal Antibody 44-3A6 as a Probe for a Novel Antigen Found on Human Lung Carcinomas with Glandular Differentiation, CANCER RESEARCH, 1985.